Durability of Antibody Responses to SARS-CoV-2 Vaccination over 12 Months in Pediatric Inflammatory Bowel Disease
Although SARS-CoV-2 antibody responses were attenuated in PIBD patients receiving anti-TNF therapy compared with vedolizumab, this did not impact protection, as seroconversion and breakthrough infection rates were similar, with no hospitalizations. These data reinforce the importance of updating vaccines and, in particular, SARS-CoV-2 vaccines in immunosuppressed PIBD patients on advanced therapies.
Authors
- Frederic Reicherz
- Gabriella K. Guerra (ORCID: https://orcid.org/0000-0003-0234-2234)
- Kevan Jacobson (ORCID: https://orcid.org/0000-0001-7269-8557)
- Marina Viñeta Paramo (ORCID: https://orcid.org/0000-0003-1096-3831)
- Pascal M. Lavoie (ORCID: https://orcid.org/0000-0002-2205-0362)
- Liam Golding (ORCID: https://orcid.org/0000-0002-8851-8052)
- Zahra Shire
- Jeffrey N. Bone (ORCID: https://orcid.org/0000-0001-7704-1677)
- Sally Lawrence (ORCID: https://orcid.org/0000-0002-7645-7053)
- Loujain Bilal
Institutions
- University of British Columbia (CA)
- Witten/Herdecke University (DE)
- BC Children's Hospital (CA)
Publication Details
- Journal
- Vaccines
- Published
- 2025-05-22
- DOI
- https://doi.org/10.3390/vaccines13060549
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- BC Children's Hospital
- Government of Canada
- Deutsche Forschungsgemeinschaft
- CH.I.L.D. Foundation
- Canadian Institutes of Health Research